HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

delta protein

Subscribe to New Research on delta protein

transmembrane protein product of the neurogenic loci delta; has homology to epidermal growth factor; ligand for NOTCH protein; amino acid sequence known; do not confuse with erythroid-specific delta factor; do not confuse with D1 protein, Drosophila

Also Known As:

D1 Notch ligand protein, Drosophila; Delta protein, Drosophila; Delta1 protein; Dll4 protein; Notch ligand delta, Drosophila; delta-1 protein; delta-like protein; deltaA protein, zebrafish; deltaC protein, zebrafish

Networked: 29 relevant articles (0 outcomes, 2 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 60567
  - Membrane Proteins: 4186
    - delta protein: 29

Experts

1.	Mochly-Rosen, Daria: 5 articles (04/2009 - 11/2003)
2.	Inagaki, Koichi: 4 articles (04/2009 - 11/2003)
3.	Shin, J: 2 articles (07/2009 - 12/2008)
4.	Lee, K: 2 articles (07/2009 - 12/2008)
5.	Latshaw, J D: 2 articles (07/2009 - 12/2008)
6.	Ikeno, Fumiaki: 2 articles (04/2009 - 11/2003)
7.	Terry, Raya D: 2 articles (05/2005 - 09/2004)
8.	Tanaka, Masashi: 2 articles (05/2005 - 09/2004)
9.	Robbins, Robert C: 2 articles (05/2005 - 09/2004)
10.	Yanez, Nicole C: 1 article (03/2010)

Related Diseases

1.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 05/01/1989 - "Studies of WT31 and delta TCS1 antibody reactivity showed that at least 4 of 13 CD3+ T-ALL cases expressed the delta protein. " 12/01/1991 - "The combinatorial repertoire of the expressed TcR-delta genes was homogeneous, as all thirteen T-ALL expressed V delta 1-D delta-J delta 1-C delta protein chains. " Order ALL the reference details at left...
2.	Myocardial Infarction 04/03/2009 - "Though we have demonstrated that inhibition of delta protein kinase C (delta PKC) at reperfusion reduces myocyte damage and improves cardiac function in a porcine acute myocardial infarction (AMI) model, impact of the selective delta PKC inhibitor on epicardial coronary endothelial function remains unknown. " 04/03/2009 - "Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infarction model." 02/19/2008 - "METHODS AND RESULTS: Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) was a "first-in-human," dose-escalation study that evaluated the safety, tolerability, and activity of KAI-9803 for patients with acute anterior ST-segment elevation MI undergoing primary percutaneous coronary intervention. " 02/19/2008 - "BACKGROUND: KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI). " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/01/2003 - "The KGN tumor cells express significantly less GRK4 alpha/beta protein and higher levels of GRK2 and GRK4 gamma/delta protein as compared to nonmalignant human granulosa cells. " 02/22/2002 - "Overexpression of the TEF-1 delta protein by transfection was oncogenic in NIH3T3 cells as evidenced by the appearance of transformed foci exhibiting anchorage-independent growth and the potential to grow as tumors in nude mice. " 08/13/1991 - "PKC-delta protein was purified from ABPL-3, a mouse myeloid tumor which expressed principally the delta isoform of PKC. " 05/01/2002 - "PKC alpha and delta protein and mRNA expression were lower in tumor tissue than in normal tissue. " 01/01/1996 - "Our results may indicate that PKC delta-like protein in Dictyostelium functions as a link between cAMP and the tumor-promoting phorbol esters, and events that take place in the nucleus." Order ALL the reference details at left...
4.	Ischemia 09/14/2004 - "BACKGROUND: Inhibiting delta protein kinase C (deltaPKC) during reperfusion and activating epsilon PKC (epsilonPKC) before ischemia each limits cardiac ischemic injury. " 11/11/2003 - "We previously found that delta-protein kinase C (deltaPKC) inhibition during simulated ischemia/reperfusion in isolated rat hearts is cardioprotective. " 02/19/2008 - "BACKGROUND: KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI). " 05/01/2005 - "CONCLUSIONS: Combined treatment with -protein kinase C activator and delta-protein kinase C inhibitor reduces ischemia-reperfusion injury and decreases the resulting graft coronary artery disease induced by prolonged ischemia." 05/01/2005 - "To determine the effect of delta-protein kinase C and -protein kinase C on ischemia-reperfusion injury and the resulting graft coronary artery disease induced by prolonged ischemia, we used a delta-protein kinase C-selective inhibitor peptide and an -protein kinase C-selective activator peptide after 30 or 120 minutes of ischemia. " Order ALL the reference details at left...
5.	Hypertrophy 12/01/2008 - "Delta-like protein 1 (DLK1) is involved in adipose and muscle development as shown by the reduction of fat mass in DLK1 transgenic mice and in muscle hypertrophy of callipyge sheep. " 07/01/2009 - "Delta-like protein 1 (DLK1) has been implicated in the muscle hypertrophy observed in DLK1 transgenic mice, callipyge sheep, and mouse paternal uniparental disomy 12 and human paternal uniparental disomy 14 syndromes. " 02/01/2008 - "The following parameters in the cultured cells were determined: surface areas of myocytes were measured by the NIH Image Software; (3)H-leucine incorporation into myocytes was counted by liquid scintillometer; mRNA expression of PPARbeta/delta, ANP, BNP, MMP9, MMP2, and IL-1beta was detected by RT-PCR; PPARbeta/delta protein expression was evaluated with immunofluorescence staining; GW0742 could ameliorate Ang II-induced cardiomyocyte hypertrophy, as indicated by its inhibitory effects on the surface area of myocytes, and ANP and BNP mRNA expressions in myocytes and (3)H-leucine incorporation into myocytes. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	KAI 9803
3.	Messenger RNA (mRNA)
4.	Protein Kinase C
5.	Interleukin-1beta (Interleukin 1 beta)
6.	Protein Kinase C-delta
7.	Protein Kinase C-epsilon
8.	PPAR-beta
9.	Proliferating Cell Nuclear Antigen (PCNA)
10.	Reactive Oxygen Species (Oxygen Radicals)

Related Therapies and Procedures

1.	Transplants (Transplant)

blog comments powered by Disqus

TREATMENT OPTIONS
for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,
Ranking and Evidence

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 42 Outcomes
Top 200 Key Drugs and Biologics
Top 23 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>